GlassScriptPhysician profile
Michaelle Halaby Holmes
NPI 1932105137
$16,400.39
in general payments reported to CMS, 2019-2025
51 companies · $3,093 in 2025
The $3,093 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,689 · 2020: $1,232 · 2021: $2,073 · 2022: $2,278 · 2023: $2,614 · 2024: $2,422 · 2025: $3,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,028 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,028.10 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,014.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,527.04 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $1,209.38 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,037.44 | 2021-2025 | |
| Amgen INC. | $967.41 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $956.85 | 2019-2025 | |
| Astellas Pharma US INC | $808.90 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $793.16 | 2021-2025 | |
| Lilly USA, LLC | $793.06 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $648.17 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Sanofi-Aventis U.S. LLC | $614.64 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $461.96 | 2019-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Abbott Laboratories | $367.42 | 2022-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $285.34 | 2019-2021 | |
| Corcept Therapeutics | $236.27 | 2023-2025 | Korlym |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michaelle Halaby Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.